Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, whether the Bexsero vaccine is licensed for (a) individual application and (b) use in conjunction with other vaccines.

Bexsero, a Meningococcal group B vaccine, was licenced for the active immunisation of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. It can be administered individually or concomitantly with a number of other vaccine antigens, either as monovalent or as combination vaccines such as diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, and varicella. When given concomitantly with other vaccines Bexsero must be administered at a separate injection site.